Leerink Partnrs Has Pessimistic Outlook of A Q2 Earnings

Agilent Technologies, Inc. (NYSE:A) – Analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for Agilent Technologies in a research report issued on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $1.32 for the quarter, down from their previous estimate of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.56 EPS and FY2027 earnings at $6.63 EPS.

A has been the topic of several other research reports. StockNews.com cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Sanford C. Bernstein cut their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a report on Tuesday, November 26th. Citigroup increased their price objective on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday. Barclays cut their target price on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a research note on Wednesday, November 27th. Finally, Evercore ISI upped their price target on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Agilent Technologies presently has a consensus rating of “Hold” and a consensus target price of $143.62.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $134.51 on Friday. The business’s 50 day moving average price is $135.85 and its 200 day moving average price is $136.48. The company has a market cap of $38.65 billion, a price-to-earnings ratio of 30.43, a PEG ratio of 4.48 and a beta of 1.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. Agilent Technologies has a one year low of $124.16 and a one year high of $155.35.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. Agilent Technologies’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS.

Institutional Trading of Agilent Technologies

A number of large investors have recently made changes to their positions in A. Massachusetts Financial Services Co. MA grew its holdings in Agilent Technologies by 5.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares in the last quarter. FMR LLC grew its stake in shares of Agilent Technologies by 62.2% during the third quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock worth $191,193,000 after purchasing an additional 493,947 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new position in Agilent Technologies in the third quarter valued at $49,449,000. Marshall Wace LLP raised its stake in Agilent Technologies by 48.6% in the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after buying an additional 313,155 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in Agilent Technologies by 63.3% during the 3rd quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock worth $87,075,000 after buying an additional 227,431 shares during the last quarter. 87.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 19.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.33% of the company’s stock.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date is Tuesday, December 31st. This represents a $0.99 annualized dividend and a dividend yield of 0.74%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.